A Novel Prognostic Marker for Primary CNS Lymphoma: Lactate Dehydrogenase-to-Lymphocyte Ratio Improves Stratification of Patients Within the Low and Intermediate MSKCC Risk Groups

• Published in: Frontiers in oncology Vol. 11; p. 696147
• Main Authors: Gao, Yuting, Wei, Li, Kim, Seok Jin, Wang, Liang, He, Yingzhi, Zheng, Yanfang, Bertero, Luca, Pellerino, Alessia, Cassoni, Paola, Tamagnone, Luca, Theresa, Prochazka Katharina, Deutsch, Alexander, Zhan, Huien, Lai, Jing, Wang, Yao, You, Hua
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 03-08-2021
• Subjects: lactate dehydrogenase-to-lymphocyte ratio; Memorial Sloan Kettering Cancer Center (MSKCC) score; neutrophil-to-lymphocyte ratio; Oncology; primary central nervous system lymphoma; prognostic parameter; Memorial Sloan Kettering Cancer Center (MSKCC) score; neutrophil-to-lymphocyte ratio; lactate dehydrogenase-to-lymphocyte ratio; prognostic parameter; primary central nervous system lymphoma
• ISSN: 2234-943X; 2234-943X
• DOI: 10.3389/fonc.2021.696147

Primary central nervous system lymphoma (PCNSL) is a highly aggressive and rare extranodal non-Hodgkin lymphoma (NHL). The MSKCC and the IELSG scores represent the most widely used prognostic models, but many changes have occurred in therapeutic protocols since their development. Moreover, many PCNSL patients cannot be classified using the IELSG score. We thus aimed to create a novel, effective and feasible prognostic model for PCNSL.
We included 248 PCNSL patients diagnosed with PCNSL. Our primary endpoint was the overall survival (OS) and we used the receiver operating characteristic (ROC) analysis to determine the optimal prognostic cut-off value for LLR (lactate dehydrogenase-to-lymphocyte ratio), neutrophil-to-lymphocyte ratio (NLR) and derived neutrophil-to-lymphocyte ratio (dNLR). Variable associated with OS were evaluated by univariate and multivariate analyses. 124 out of 248 patients were randomly selected as the internal validation cohort.
By univariate analysis, an age >60 years, Eastern Cooperative Oncology Group performance status (ECOG PS) >1, treatment with radiotherapy alone, high-risk groups of Memorial Sloan Kettering Cancer Center (MSKCC) score, NLR >4.74, dNLR >3.29, and LLR >166.8 were significantly associated with a worse OS. By multivariate analysis, the MSKCC score and LLR were confirmed as independent prognostic parameters for poorer OS. OS, however, was not significantly different between low- and intermediate-risk groups according to the MSKCC score, while LLR proved to be prognostically relevant and was thus used to develop a novel, effective three-tier PCNSL scoring system. Of 124 patients, 84 patients with survival data and LLR data were successfully validated by newly established PCNSL LLR scoring system.
In the present study, we demonstrate that a high LLR represents an independent unfavorable prognostic parameter in PCNSL patients which can be integrated into an effective prognostic model.